K
KSQ Therapeutics
The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates
About KSQ Therapeutics
KSQ Therapeutics is a biotechnology startup operating in the healthcare sector, specifically in the development of innovative cancer treatments. The company's primary focus is on the discovery and development of the best therapeutic targets for disease intervention, with a particular emphasis on solid tumors. KSQ Therapeutics serves a broad range of clients, including patients suffering from various forms of cancer and healthcare providers seeking effective treatment options.
The company's business model revolves around the development and commercialization of its proprietary eTIL (gene-edited Tumor Infiltrating Lymphocyte) cell therapy products. These products, developed using KSQ's CRISPRomics platform and CRISPR2 technology, have shown promising results in preclinical tumor models. The company's lead programs, KSQ-001 and KSQ-004, aim to maximize the ability of tumor-targeting T cells to destroy solid tumors.
KSQ Therapeutics generates revenue through the development, clinical testing, and eventual commercialization of its eTIL products. The company's simplified ExPRESS™ eTIL manufacturing process promises quicker turnaround times from tumor to vein, potentially improving the patient experience and reducing costs.
The company operates in a highly competitive market, with many other biotech companies also working on innovative cancer treatments. However, KSQ's unique approach and promising early results set it apart in this field.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 60
- Open positions
- None listed
- Dealroom signal
- 63.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Genetics and genomics, Crispr, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Sep 2018 | $80M | $320M | Polaris Partners · Baillie Gifford · Invus · ARCH Venture Partners | — |
| LATE VCOther financing | Oct 2017 | $76M | $304M | Alexandria Equities · Polaris Partners · ARCH Venture Partners · Flagship Pioneering | ↗ |
Growth signals
Latest recorded traffic for KSQ Therapeutics is 4.3K monthly website visits, up 38.7% over the last three months. KSQ Therapeutics's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
KSQ Therapeutics in the Cambridge ecosystem
The KSQ Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later7 investors entered at this stage
Alexandria Equities
Polaris Partners
ARCH Venture Partners
Flagship Pioneering
Baillie Gifford
Invus
Lilly Asia Ventures
Other known investors1 additional known investor
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about KSQ Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See KSQ Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










